Clinical trials: sponsored by Deciphera Pharmaceuticals, LLC
GIST
A Study of Inlexisertib (DCC-3116) in Combination With Anticancer Therapies in Participants With Advanced Malignancies
This is a Phase 1/2, multicenter, open-label (unless otherwise specified in a combination-specific module) study of inlexisertib in combination with anticancer therapies.
- Trial name
- NCT05957367
- Testing
- Inlexisertib, Ripretinib
- Where
- 28 sites in United States, Denmark and 7 more
- Volunteers
- 94 people
- Sponsor
- Deciphera Pharmaceuticals, LLC
Gastrointestinal Stromal Tumors
A Study of Ripretinib vs Sunitinib in Advanced GIST Patients After Treatment With Imatinib
This is a 2-arm, randomized, open-label, international, multicenter study comparing the efficacy of ripretinib to sunitinib in GIST patients who progressed on or were intolerant to first-line anticancer treatment with imatinib.
- Trial name
- INTRIGUE (NCT03673501)
- Testing
- Ripretinib, Sunitinib
- Where
- 121 sites in United States, Argentina and 20 more
- Volunteers
- 453 people
- Sponsor
- Deciphera Pharmaceuticals, LLC
Healthy Participants
Evaluate the Effect of Vimseltinib on Pharmacokinetics of Combined Oral Contraceptive (Ethinyl Estradiol/Levonorgestrel)
The main purpose of this study is to determine the effect of vimseltinib on pharmacokinetics of combined oral contraceptive (COC) (ethinyl estradiol/levonorgestrel) in healthy female participants.
- Trial name
- NCT07539090
- Testing
- Vimseltinib, Combined Oral Contraceptive (COC) (ethinyl estradiol [EE]/levonorgestrel [LNG])
- Where
- United States
- Volunteers
- 27 people, healthy volunteers welcome
- Sponsor
- Deciphera Pharmaceuticals, LLC
Healthy Male Participants
Evaluate the Effect of Vimseltinib on P-glycoprotein (P-gp) Inhibition in Healthy Male Participants
The main purpose of this study is to determine the effect of vimseltinib on pharmacokinetics of P-glycoprotein (P-gp) substrate (dabigatran) in healthy male participants. This study will last approximately 21 days.
- Trial name
- NCT07744802
- Testing
- Vimseltinib, Dabigatran
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Deciphera Pharmaceuticals, LLC
Renal Cell Carcinoma, Urothelial Carcinoma
Study of DCC-2812 in Participants With Advanced Genitourinary Cancers
This is a multicenter clinical trial to evaluate the safety and preliminary activity of the selective general control nonderepressible 2 (GCN2) activator DCC-2812 as monotherapy in advanced/metastatic renal cell carcinoma (RCC)…
- Conditions
- Renal Cell Carcinoma, Urothelial Carcinoma, Castration-resistant Prostate Cancer
- Trial name
- NCT06966024
- Testing
- DCC-2812
- Where
- 8 sites in United States
- Volunteers
- 60 people
- Sponsor
- Deciphera Pharmaceuticals, LLC
Tenosynovial Giant Cell Tumor
MOVE: Tenosynovial Giant Cell Tumor (TGCT) Real-World Participant Experience With Vimseltinib
The goal of this observational study is to better understand real-world use of vimseltinib, treatment patterns, and health-related quality of life in participants treated with vimseltinib for TGCT.
- Trial name
- MOVE (NCT07075471)
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- Deciphera Pharmaceuticals, LLC
Advanced Malignant Neoplasm, Pigmented Villonodular Synovitis
Study of Vimseltinib (DCC-3014) in Patients With Advanced Tumors and Tenosynovial Giant Cell Tumor
This is a multicenter, open-label Phase 1/2 study of vimseltinib in patients with malignant solid tumors and tenosynovial giant cell tumor (TGCT).
- Conditions
- Advanced Malignant Neoplasm, Pigmented Villonodular Synovitis, Giant Cell Tumor of Tendon Sheath, Tenosynovial Giant Cell Tumor
- Trial name
- NCT03069469
- Testing
- Vimseltinib
- Where
- 24 sites in United States, Australia and 7 more
- Volunteers
- 120 people
- Sponsor
- Deciphera Pharmaceuticals, LLC
Non-Small Cell Lung Cancer, Advanced Solid Tumor
Study of Inlexisertib (DCC-3116) in Participants With RAS/MAPK Pathway Mutant Solid Tumors
This is a multicenter, open label, first in human (FIH) study of inlexisertib as monotherapy, and in combination with trametinib, binimetinib, or sotorasib in participants with advanced or metastatic solid tumors with RAS/MAPK…
- Conditions
- Non-Small Cell Lung Cancer, Advanced Solid Tumor, Metastatic Solid Tumor
- Trial name
- NCT04892017
- Testing
- Inlexisertib, Trametinib, Binimetinib
- Where
- 10 sites in United States
- Volunteers
- 91 people
- Sponsor
- Deciphera Pharmaceuticals, LLC
Tenosynovial Giant Cell Tumor, Pigmented Villonodular Synovitis
Study of Vimseltinib for Tenosynovial Giant Cell Tumor
This is a multicenter Phase 3 clinical study, which aims to evaluate the effectiveness of an investigational drug called vimseltinib for the treatment of tenosynovial giant cell tumor (TGCT) in cases where surgical removal of the…
- Conditions
- Tenosynovial Giant Cell Tumor, Pigmented Villonodular Synovitis, Giant Cell Tumor of Tendon Sheath, Tenosynovial Giant Cell Tumor, Diffuse
- Trial name
- MOTION (NCT05059262)
- Testing
- Vimseltinib
- Where
- 35 sites in United States, Australia and 11 more
- Volunteers
- 123 people
- Sponsor
- Deciphera Pharmaceuticals, LLC
Advanced Solid Tumor, RAF Mutation
Study of DCC-3084 in Participants With Advanced Malignancies Driven by the Mitogen-Activated Protein Kinase (MAPK) Pathway
This is a multicenter clinical trial to evaluate DCC-3084 alone or in combination with other cancer therapies in participants with advanced cancers. Module A will enroll participants with advanced/metastatic solid tumors.
- Conditions
- Advanced Solid Tumor, RAF Mutation, RAS Mutation, NF1 Mutation
- Trial name
- NCT06287463
- Testing
- DCC-3084
- Where
- 9 sites in United States
- Volunteers
- 29 people
- Sponsor
- Deciphera Pharmaceuticals, LLC
Healthy Participants
Evaluate the Effect of Vimseltinib on Organic Cation Transporter 2 (OCT2)
The main purpose of this study is to evaluate the effect of multiple doses of vimseltinib on the pharmacokinetics (PK) of a clinical OCT2 substrate (metformin) in healthy male participants.
- Trial name
- NCT07158411
- Testing
- Vimseltinib, Metformin
- Where
- United States
- Volunteers
- 22 people, healthy volunteers welcome
- Sponsor
- Deciphera Pharmaceuticals, LLC
Gastrointestinal Stromal Tumor (GIST)
A Master Protocol to Evaluate DCC-3009 in Gastrointestinal Stromal Tumor (GIST)
The purpose of this Phase 1/2 master protocol study is to evaluate if DCC-3009 is safe, tolerable and works effectively in the treatment of GIST.
- Trial name
- NCT06630234
- Testing
- DCC-3009
- Where
- 10 sites in United States
- Volunteers
- 120 people
- Sponsor
- Deciphera Pharmaceuticals, LLC
Healthy Participants
Evaluate the Effect of Vimseltinib on the Pharmacokinetics of a BCRP and OATP1B1 Substrate
The main purpose of this study is to determine the effect of Vimseltinib dosing on breast cancer resistance protein (BCRP) and organic-anion-transporting polypeptide 1 B1 (OAT1PB1) activity by using rosuvastatin in healthy male…
- Trial name
- NCT07158398
- Testing
- Vimseltinib, Rosuvastatin
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Deciphera Pharmaceuticals, LLC
GIST
A Study of Ripretinib vs Sunitinib in Patients With Advanced GIST With Specific KIT Exon Mutations Who Were Previously Treated With Imatinib
This is a Phase 3, 2-arm, randomized, open-label, global, multicenter study comparing the efficacy of ripretinib to sunitinib in participants with GIST who progressed on first-line treatment with imatinib, harbor co-occurring KIT…
- Trial name
- INSIGHT (NCT05734105)
- Testing
- Ripretinib, Sunitinib
- Where
- 70 sites in United States, Australia and 13 more
- Volunteers
- 54 people
- Sponsor
- Deciphera Pharmaceuticals, LLC
Chronic Graft-Versus-Host Disease (cGVHD)
A Study to Evaluate Vimseltinib in Adults With Active Chronic Graft-Versus-Host Disease (cGVHD)
The purpose of this study is to determine if vimseltinib is safe, tolerable and works effectively to treat adults with active moderate to severe cGVHD.
- Trial name
- NCT06619561
- Testing
- Vimseltinib
- Where
- 26 sites in United States
- Volunteers
- 48 people
- Sponsor
- Deciphera Pharmaceuticals, LLC
Locally Advanced or Metastatic Solid Tumor
A Phase 1b/2 Study of Rebastinib (DCC-2036) in Combination With Paclitaxel in Patients With Advanced or Metastatic Solid Tumors
This is an open-label Phase 1b/2 multicenter study of rebastinib (DCC-2036) in combination with paclitaxel designed to evaluate the safety, tolerability, and pharmacokinetics (PK) in patients with advanced or metastatic solid…
- Trial name
- NCT03601897
- Testing
- Rebastinib, Paclitaxel
- Where
- 14 sites in United States
- Volunteers
- 177 people
- Sponsor
- Deciphera Pharmaceuticals, LLC
Locally Advanced or Metastatic Solid Tumor
A Study of Rebastinib (DCC-2036) in Combination With Carboplatin in Patients With Advanced or Metastatic Solid Tumors
This is an open-label Phase 1b/2 multicenter study of rebastinib (DCC-2036) in combination with carboplatin designed to evaluate the safety, tolerability, and pharmacokinetics (PK) in participants with advanced or metastatic…
- Trial name
- NCT03717415
- Testing
- Rebastinib, Carboplatin
- Where
- 9 sites in United States
- Volunteers
- 70 people
- Sponsor
- Deciphera Pharmaceuticals, LLC
GIST - Gastrointestinal Stromal Tumor
A Drug-Drug Interaction Study to Evaluate the Effect of Ripretinib on the Pharmacokinetics of a CYP2C8 Probe Substrate in Patients with Advanced GIST
Evaluate the Effect of Ripretinib on the Pharmacokinetics of a CYP2C8 Substrate
- Trial name
- NCT04530981
- Testing
- Ripretinib, Repaglinide
- Where
- 3 sites in United States
- Volunteers
- 13 people
- Sponsor
- Deciphera Pharmaceuticals, LLC
Gastrointestinal Stromal Tumors, Advanced Systemic Mastocytosis
A Safety, Tolerability and PK Study of DCC-2618 in Patients With Advanced Malignancies
This is a Phase 1, open-label, first-in-human (FIH) dose-escalation study designed to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary antitumor activity of DCC-2618, administered…
- Conditions
- Gastrointestinal Stromal Tumors, Advanced Systemic Mastocytosis, Advanced Cancers
- Trial name
- NCT02571036
- Testing
- DCC-2618
- Where
- 26 sites in United States, Canada and 4 more
- Volunteers
- 282 people
- Sponsor
- Deciphera Pharmaceuticals, LLC
Gastrointestinal Stromal Tumors
Phase 3 Study of DCC-2618 vs Placebo in Advanced GIST Patients Who Have Been Treated With Prior Anticancer Therapies
This is a 2-arm, randomized, placebo-controlled, double-blind, international, multicenter study comparing the efficacy of ripretinib (DCC-2618) to placebo in patients who have received treatment with prior anticancer therapies.
- Trial name
- INVICTUS (NCT03353753)
- Testing
- DCC-2618
- Where
- 35 sites in United States, Australia and 11 more
- Volunteers
- 129 people
- Sponsor
- Deciphera Pharmaceuticals, LLC